Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00258_DB01212_nanopub.RAumitTE3frk81lj88Zvr7K7i_YEOHV1jEH50uqqdVJuY#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00258_DB01212 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00258_DB01212 label "DDI between Calcium Acetate and Ceftriaxone - Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. [drugbank_resource:DB00258_DB01212]" assertion.
- drugbank_resource:DB00258_DB01212 identifier "drugbank_resource:DB00258_DB01212" assertion.
- drugbank_resource:DB00258_DB01212 title "DDI between Calcium Acetate and Ceftriaxone - Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion." assertion.
- drugbank:DB01212 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00258_DB01212 assertion.
- drugbank:DB00258 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00258_DB01212 assertion.